

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS AND
INDEPENDENT AUDITORS' REVIEW REPORT
MARCH 31, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

INDEPENDENT AUDITORS' REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of METATECH (AP) INC.

Introduction

We have reviewed the accompanying consolidated balance sheets of Metatech (AP) INC. and subsidiaries (the "Group") as at March 31, 2025 and 2024, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the three-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410 "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at March 31, 2025 and 2024, and of its consolidated financial performance and its consolidated cash flows for the three-month periods then ended in accordance with “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission.

LIN, KUAN-HUNG

Wang, Fang-Yu

For and on behalf of PricewaterhouseCoopers, Taiwan

May 8, 2025

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2025, DECEMBER 31, 2024 AND MARCH 31, 2024
(Expressed in thousands of New Taiwan dollars)

Assets	Notes	<u>March 31, 2025</u>		<u>December 31, 2024</u>		<u>March 31, 2024</u>		
		AMOUNT	%	AMOUNT	%	AMOUNT	%	
Current Assets								
1100	Cash and cash equivalents	6(1)	\$ 1,538,906	46	\$ 1,618,500	50	\$ 1,861,672	57
1136	Current financial assets at amortised cost	6(2) and 8	9,800	-	34,300	1	234,400	7
1150	Notes receivable, net	6(3)	5	-	46	-	572	-
1170	Accounts receivable, net	6(3)	389,761	12	366,526	11	320,738	10
1200	Other receivables		3,846	-	4,581	-	2,671	-
1220	Current income tax assets		9,963	-	9,273	-	7,382	-
130X	Inventories	6(4)	82,578	3	77,397	2	51,623	1
1410	Prepayments		62,362	2	51,296	2	19,643	1
1470	Other current assets		750	-	939	-	19	-
11XX	Current Assets		<u>2,097,971</u>	<u>63</u>	<u>2,162,858</u>	<u>66</u>	<u>2,498,720</u>	<u>76</u>
Non-current assets								
1550	Investments accounted for using the equity method	6(5)	10,189	-	10,733	-	13,527	1
1600	Property, plant and equipment	6(6) and 8	833,829	25	716,182	22	370,439	11
1755	Right-of-use assets	6(7)	96,203	3	102,237	3	95,518	3
1780	Intangible assets	6(8)	188,514	6	190,463	6	196,315	6
1840	Deferred income tax assets	6(21)	64,094	2	64,120	2	77,421	2
1900	Other non-current assets	6(10)	32,809	1	25,019	1	24,597	1
15XX	Non-current assets		<u>1,225,638</u>	<u>37</u>	<u>1,108,754</u>	<u>34</u>	<u>777,817</u>	<u>24</u>
1XXX	Total assets		<u>\$ 3,323,609</u>	<u>100</u>	<u>\$ 3,271,612</u>	<u>100</u>	<u>\$ 3,276,537</u>	<u>100</u>

(Continued)

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2025, DECEMBER 31, 2024 AND MARCH 31, 2024
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity		Notes	March 31, 2025		December 31, 2024		March 31, 2024	
			AMOUNT	%	AMOUNT	%	AMOUNT	%
Current Liabilities								
2100	Short-term borrowings	6(9) and 8	\$ 361,000	11	\$ 324,000	10	\$ 294,000	9
2130	Current contract liabilities	6(15)	24,652	1	24,863	1	19,120	1
2150	Notes payable		894	-	1,006	-	1,661	-
2170	Accounts payable	7	134,622	4	137,347	4	79,001	2
2200	Other payables	7	104,564	3	50,839	1	41,410	1
2230	Current income tax liabilities		345	-	581	-	718	-
2280	Current lease liabilities	7	23,879	-	24,107	1	18,216	1
2399	Other current liabilities, others		1,265	-	1,881	-	1,316	-
21XX	Current Liabilities		<u>651,221</u>	<u>19</u>	<u>564,624</u>	<u>17</u>	<u>455,442</u>	<u>14</u>
Non-current liabilities								
2570	Deferred income tax liabilities	6(21)	16,063	1	14,952	-	23,697	1
2580	Non-current lease liabilities	7	78,643	2	84,460	3	83,545	2
2600	Other non-current liabilities		300	-	300	-	300	-
25XX	Non-current liabilities		<u>95,006</u>	<u>3</u>	<u>99,712</u>	<u>3</u>	<u>107,542</u>	<u>3</u>
2XXX	Total Liabilities		<u>746,227</u>	<u>22</u>	<u>664,336</u>	<u>20</u>	<u>562,984</u>	<u>17</u>
Equity								
Equity attributable to owners of the parent								
Share capital								
3110	Share capital - common stock	6(12)	681,726	20	681,726	21	681,726	21
Capital surplus								
3200	Capital surplus	6(13)	679,028	21	678,639	21	677,556	21
Retained earnings								
3350	Accumulated deficit	6(14)	(248,190)	(8)	(234,718)	(7)	(192,036)	(6)
Other equity								
3400	Other equity interest		24,696	1	19,278	-	8,163	-
3500	Treasury shares	6(12)	(1,864)	-	(1,864)	-	(1,864)	-
31XX	Equity attributable to owners of the parent		<u>1,135,396</u>	<u>34</u>	<u>1,143,061</u>	<u>35</u>	<u>1,173,545</u>	<u>36</u>
36XX	Non-controlling interests	4(3)	<u>1,441,986</u>	<u>44</u>	<u>1,464,215</u>	<u>45</u>	<u>1,540,008</u>	<u>47</u>
3XXX	Total equity		<u>2,577,382</u>	<u>78</u>	<u>2,607,276</u>	<u>80</u>	<u>2,713,553</u>	<u>83</u>
Significant contingent liabilities and unrecognised contract commitments								
Significant events after the balance sheet date								
3X2X	Total liabilities and equity		<u>\$ 3,323,609</u>	<u>100</u>	<u>\$ 3,271,612</u>	<u>100</u>	<u>\$ 3,276,537</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars, except loss per share amount)

				Three months ended March 31				
				2025		2024		
Items	Notes	AMOUNT	%	AMOUNT	%			
4000	Sales revenue	6(15) and 7	\$	387,278	100	\$	330,088	100
5000	Operating costs	6(4)(19)(20)	(340,830)	(88)	(298,129)	(90)
5950	Net operating margin			46,448	12		31,959	10
	Operating expenses	6(19)(20)						
6100	Selling expenses		(29,867)	(8)	(22,935)	(7)
6200	General and administrative expenses		(38,840)	(10)	(44,650)	(14)
6300	Research and development expenses		(31,581)	(8)	(26,117)	(8)
6450	Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	12(2)	(1)	-	(-	-
6000	Total operating expenses		(100,289)	(26)	(93,702)	(29)
6900	Operating loss		(53,841)	(14)	(61,743)	(19)
	Non-operating revenue and expenses							
7100	Interest income	6(16)		8,096	2		11,538	4
7010	Other income			213	-		290	-
7020	Other gains and losses	6(17)		11,209	3		16,845	5
7050	Finance costs	6(18)	(2,367)	(1)	(2,081)	(1)
7060	Share of loss of associates and joint ventures accounted for using the equity method		(544)	-	(1,354)	-
7000	Total non-operating revenue and expenses			16,607	4		25,238	8
7900	Loss before income tax		(37,234)	(10)	(36,505)	(11)
7950	Income tax (expense) benefit	6(21)	(842)	-	(2,970)	(1)
8200	Loss for the period		(\$	38,076)	(10)	(\$	39,475)	(12)
	Other comprehensive income (net)							
	Components of other comprehensive income that will be reclassified to profit or loss							
8361	Financial statements translation differences of foreign operations		\$	6,769	2	\$	20,829	6
8399	Income tax relating to the components of other comprehensive income	6(21)	(1,355)	-	(4,166)	(1)
8360	Components of other comprehensive income that will be reclassified to profit or loss			5,414	2		16,663	5
8300	Total other comprehensive income for the period		\$	5,414	2	\$	16,663	5
8500	Total comprehensive loss for the period		(\$	32,662)	(8)	(\$	22,812)	(7)
	Loss attributable to:							
8610	Owners of the parent		(\$	13,472)	(4)	(\$	25,341)	(8)
8620	Non-controlling interests		(24,604)	(6)	(14,134)	(4)
			(\$	38,076)	(10)	(\$	39,475)	(12)
	Other comprehensive loss attributable to:							
8710	Owners of the parent		(\$	8,054)	(2)	(\$	8,678)	(3)
8720	Non-controlling interests		(24,608)	(6)	(14,134)	(4)
			(\$	32,662)	(8)	(\$	22,812)	(7)
	Basic loss per share	6(22)						
9750	Total basic loss per share		(\$	0.20)		(\$	0.37)	
9850	Total diluted loss per share		(\$	0.20)		(\$	0.37)	

The accompanying notes are an integral part of these consolidated financial statements.

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

Equity attributable to owners of the parent											
Notes	Capital Reserves						Other Equity	Treasury shares	Total	Non-controlling interests	Total equity
	Share capital - common stock	Additional paid-in capital	Capital Surplus, changes in ownership interests in subsidiaries	Employee stock warrants	Others	Legal reserve	Financial statements translation differences of foreign operations				
<u>2024</u>											
Balance at January 1, 2024	\$ 681,726	\$ 617,151	\$ 1,669	\$ 47,154	\$ 11,194	(\$ 166,695)	(\$ 8,500)	(\$ 1,864)	\$ 1,181,835	\$ 1,551,944	\$ 2,733,779
Loss for the period	-	-	-	-	-	(25,341)	-	-	(25,341)	(14,134)	(39,475)
Other comprehensive income (loss)	-	-	-	-	-	-	16,663	-	16,663	-	16,663
Total comprehensive loss	-	-	-	-	-	(25,341)	16,663	-	(8,678)	(14,134)	(22,812)
Share-based payments 6(11)	-	-	388	-	-	-	-	-	388	2,198	2,586
Balance at March 31, 2024	<u>\$ 681,726</u>	<u>\$ 617,151</u>	<u>\$ 2,057</u>	<u>\$ 47,154</u>	<u>\$ 11,194</u>	<u>(\$ 192,036)</u>	<u>\$ 8,163</u>	<u>(\$ 1,864)</u>	<u>\$ 1,173,545</u>	<u>\$ 1,540,008</u>	<u>\$ 2,713,553</u>
<u>2025</u>											
Balance at January 1, 2025	\$ 681,726	\$ 617,151	\$ 3,140	\$ -	\$ 58,348	(\$ 234,718)	\$ 19,278	(\$ 1,864)	\$ 1,143,061	\$ 1,464,215	\$ 2,607,276
Loss for the period	-	-	-	-	-	(13,472)	-	-	(13,472)	(24,604)	(38,076)
Other comprehensive income (loss)	-	-	-	-	-	-	5,418	-	5,418	(4)	5,414
Total comprehensive income (loss)	-	-	-	-	-	(13,472)	5,418	-	(8,054)	(24,608)	(32,662)
Share-based payments 6(11)	-	-	381	-	-	-	-	-	381	2,156	2,537
Changes in the equity of the subsidiary based on the shareholding ratio 6(23)	-	-	8	-	-	-	-	-	8	223	231
Balance at March 31, 2025	<u>\$ 681,726</u>	<u>\$ 617,151</u>	<u>\$ 3,529</u>	<u>\$ -</u>	<u>\$ 58,348</u>	<u>(\$ 248,190)</u>	<u>\$ 24,696</u>	<u>(\$ 1,864)</u>	<u>\$ 1,135,396</u>	<u>\$ 1,441,986</u>	<u>\$ 2,577,382</u>

The accompanying notes are an integral part of these consolidated financial statements.

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Three-month periods ended March 31	
		2025	2024
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Loss before tax		(\$ 37,234)	(\$ 36,505)
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation expense (including right-of-use assets)	6(6)(7)(19)	13,377	11,506
Amortization expense	6(19)	2,706	2,240
Expected credit loss	12(2)	(1)	-
Interest expense	6(18)	2,367	2,081
Interest income	6(16)	(8,096)	(11,538)
Share-based compensation cost	6(11)	2,537	2,586
Share of loss of associates and joint ventures accounted for using the equity method		544	1,354
Gains arising from lease modifications	6(17)	(3)	-
Changes in operating assets and liabilities			
Changes in operating assets			
Notes receivable		41	(167)
Accounts receivable		(23,234)	(67,059)
Other receivables		735	(513)
Prepayments		(11,066)	(5,301)
Inventories		(5,181)	18,452
Other current assets		189	425
Net defined benefit assets		(4)	4
Changes in operating liabilities			
Contract liabilities		(211)	5,515
Notes payable		(112)	(796)
Accounts payable		(2,725)	1,630
Other payables		6,312	3,697
Other current liabilities		(616)	342
Cash outflow generated from operations		(59,675)	(72,047)
Interest received		8,096	11,538
Interest paid		(2,367)	(2,081)
Interest taxes paid		-	(1,909)
Interest taxes received		713	-
Net cash flows used in operating activities		(53,233)	(64,499)

(Continued)

METATECH (AP) INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Three-month periods ended March 31	
		2025	2024
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at amortised cost		\$ -	(\$ 223,100)
Proceeds from repayments of financial assets at amortised cost		24,500	-
Acquisition of property, plant and equipment	6(24)	(77,514)	(90,036)
Decrease in guarantee deposit received		114	1,853
Increase in other non-current assets		(8,657)	(3,511)
Net cash flows used in investing activities		(61,557)	(314,794)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term borrowings	6(25)	37,000	-
Repayment of principal portion of lease liabilities	6(25)	(6,106)	(5,651)
Exercise of employee stock		231	-
Net cash flows from (used in) financing activities		31,125	(5,651)
Effect of exchange rate changes on cash and cash equivalents		4,071	18,086
Net decrease in cash and cash equivalents		(79,594)	(366,858)
Cash and cash equivalents at beginning of period	6(1)	1,618,500	2,228,530
Cash and cash equivalents at end of period	6(1)	<u>\$ 1,538,906</u>	<u>\$ 1,861,672</u>

The accompanying notes are an integral part of these consolidated financial statements.

METATECH (AP) INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. History and Organisation

METATECH (AP) Inc. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) in September 1998. The Company and its subsidiaries (collectively referred herein as the “Group”) are primarily engaged in wholesale and retail of electronic products and equipment as well as development and operation of biomedicine related business. The shares of the Company were officially listed on the Taipei Exchange on June 3, 2004 as approved by the Financial Supervisory Commission.

2. The Date of Authorisation for Issuance of the Financial Statements and Procedures for Authorisation

These consolidated financial statements were reported to the Board of Directors on May 8, 2025.

3. Application of New Standards, Amendments and Interpretations

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS[®]”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by FSC and became effective from 2025 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Amendments to IAS 21, ‘Lack of exchangeability’	January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2025 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’	January 1, 2026

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

<u>New Standards, Interpretations and Amendments</u>	<u>Effective date by International Accounting Standards Board</u>
Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’	January 1, 2026
Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-dependent electricity’	January 1, 2026
Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’	To be determined by International Accounting Standards Board
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 – comparative information’	January 1, 2023
IFRS 18, ‘Presentation and disclosure in financial statements’	January 1, 2027
IFRS 19, ‘Subsidiaries without public accountability: disclosures’	January 1, 2027
Annual Improvements to IFRS Accounting Standards—Volume 11	January 1, 2026

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

4. Summary of Material Accounting Policies

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and the International Accounting Standard 34, ‘Interim financial reporting’ that came into effect as endorsed by the FSC.

(2) Basis of preparation

A. Except for the following items, the consolidated financial statements have been prepared under the historical cost convention:

Defined benefit assets recognised based on the net amount of pension fund assets less present value of defined benefit obligation.

B. The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

A. Basis for preparation of consolidated financial statements:

(a) All subsidiaries are included in the Group's consolidated financial statements. Subsidiaries are all entities (including structured entities) controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries.

(b) Inter-company transactions, balances and unrealised gains or losses on transactions between companies within the Group are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

(c) Changes in a parent's ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary (transactions with non-controlling interests) are accounted for as equity transactions, i.e. transactions with owners in their capacity as owners. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity.

(d) When the Group loses control of a subsidiary, the Group remeasures any investment retained in the former subsidiary at its fair value. That fair value is regarded as the fair value on initial recognition of a financial asset or the cost on initial recognition of the associate or joint venture. Any difference between fair value and carrying amount is recognised in profit or loss. All amounts previously recognised in other comprehensive income in relation to the subsidiary are reclassified to profit or loss on the same basis as would be required if the related assets or liabilities were disposed of. That is, when the Group loses control of a subsidiary, all gains or losses previously recognised in other comprehensive income in relation to the subsidiary should be reclassified from equity to profit or loss, if such gains or losses would be reclassified to profit or loss when the related assets or liabilities are disposed of.

B. Subsidiaries included in the consolidated financial statements:

Name of investor	Name of subsidiary	Main business activities	Ownership(%)			Description
			March 31, 2025	December 31, 2024	March 31, 2024	
The Company	MetaTech Investment Holding Co., Ltd. (MetaTech Investment)	Investment holding and reinvestment business	100	100	100	Note 1
"	Chienhwa Travel Service Co., Ltd.	Travel business	100	100	100	"
"	LOCUS CELL CO., LTD.	Cell R&D and production business	15	15	15	Note 1、2
MetaTech Investment	MTI Holding Co., Ltd. (MTI Holding)	Investment holding and reinvestment business	100	100	100	Note 1
MTI Holding	MetaTech (S) Pte Ltd. (MetaTech(S))	Wholesale and retail of electronic materials	100	100	100	"
"	MetaTech Ltd.	Wholesale and retail of electronic materials	100	100	100	"
MetaTech Ltd.	MetaTech (Shenzhen) Ltd. (MetaTech (SZ))	Wholesale and retail of electronic materials	100	100	100	"
LOCUS CELL CO., LTD.	Locus Ltd.	Sales of Regenerative Medicine Products	100	-	-	Note 3

Note 1: The information included in these consolidated financial statements as at March 31, 2025 and 2024 is based on the reviewed financial statements of each company. And the information included in these consolidated financial statements as at December 31, 2024 is based on the audited financial statements of each company.

Note 2: The Company has assessed that it has control over the company's business and personnel, so it is included in the consolidated financial statements.

Note 3: The company was established and invested during 2025.

C. Subsidiaries not included in the consolidated financial statements: None.

D. Adjustments for subsidiaries with different balance sheet dates: None.

E. Significant restrictions:

Cash and short-term deposits of \$52,670 deposited in mainland China are under local foreign exchange control which restricts the capital to be remitted outside the borders (except for normal dividend distribution).

F. Subsidiaries that have non-controlling interests that are material to the Group:

As of March 31, 2025, December 31, 2024 and March 31, 2024, the non-controlling interest amounted to \$1,441,986, \$1,464,215 and \$1,540,008, respectively. The information of non-controlling interest and respective subsidiaries is as follows:

		Non-controlling interest	
		March 31, 2025	
Name of subsidiary	Principal place of business	Amount	Ownership(%)
LOCUS CELL CO., LTD	Taiwan	\$ 1,441,986	85%

		Non-controlling interest	
		December 31, 2024	
Name of subsidiary	Principal place of business	Amount	Ownership(%)
LOCUS CELL CO., LTD	Taiwan	\$ 1,464,215	85%

		Non-controlling interest	
		March 31, 2024	
Name of subsidiary	Principal place of business	Amount	Ownership(%)
LOCUS CELL CO., LTD	Taiwan	\$ 1,540,008	85%

Summarised financial information of the subsidiaries:

Balance sheets

	LOCUS CELL CO., LTD.		
	March 31, 2025	December 31, 2024	March 31, 2024
Current assets	\$ 1,085,801	\$ 1,187,622	\$ 1,619,944
Non-current assets	757,406	631,382	282,302
Current liabilities	(91,236)	(38,299)	(30,780)
Non-current liabilities	(55,548)	(58,099)	(59,692)
Total net assets	\$ 1,696,423	\$ 1,722,606	\$ 1,811,774

Statements of comprehensive income:

	LOCUS CELL CO., LTD.	
	Three-month periods ended March 31,	
	2025	2024
Revenue	\$ 757	\$ 406
Loss before income tax	(28,946)	(16,628)
Income tax expense	-	-
Loss for the period from continuing operations	(28,946)	(16,628)
Loss from discontinued operations	-	-
Loss for the period	(28,946)	(16,628)
Other comprehensive income, net of tax	(5)	-
Total comprehensive loss for the period	(\$ 28,951)	(\$ 16,628)
Comprehensive loss attributable to non-controlling interest	(\$ 24,608)	(\$ 14,134)
Dividends paid to non-controlling interest	\$ -	\$ -

Statements of cash flows

	LOCUS CELL CO., LTD.	
	Three-month periods ended March 31,	
	2025	2024
Net cash flows used in operating activities	(\$ 24,908)	(\$ 16,508)
Net cash flows used in investing activities	(64,918)	(312,579)
Net cash flows used in financing activities	(3,986)	(3,711)
Effect of exchange rates on cash and cash equivalents	-	-
Decrease in cash and cash equivalents	(93,812)	(332,798)
Cash and cash equivalents, beginning of period	1,121,053	1,708,167
Cash and cash equivalents, end of period	\$ 1,027,241	\$ 1,375,369

(4) Foreign currency translation

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in New Taiwan Dollars, which is the Company's functional and the Group's presentation currency.

A. Foreign currency transactions and balances

- (a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognised in profit or loss in the period in which they arise.
- (b) Monetary assets and liabilities denominated in foreign currencies at the period end are re-translated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognised in profit or loss.
- (c) Non-monetary assets and liabilities denominated in foreign currencies held at fair value through profit or loss are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in profit or loss. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through other comprehensive income are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in other comprehensive income. However, non-monetary assets and liabilities denominated in foreign currencies that are not measured at fair value are translated using the historical exchange rates at the dates of the initial transactions.
- (d) All foreign exchange gains and losses are presented in the statement of comprehensive income within 'other gains and losses'.

B. Translation of foreign operations

The operating results and financial position of all the Group entities that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- (a) Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;

- (b) Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and
- (c) All resulting exchange differences are recognised in other comprehensive income.

(5) Classification of current and non-current items

- A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:
 - (a) Assets arising from operating activities that are expected to be realised, or are intended to be sold or consumed within the normal operating cycle;
 - (b) Assets held mainly for trading purposes;
 - (c) Assets that are expected to be realised within twelve months from the balance sheet date;
 - (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to settle liabilities more than twelve months after the balance sheet date.
- B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:
 - (a) Liabilities that are expected to be settled within the normal operating cycle;
 - (b) Liabilities arising mainly from trading activities;
 - (c) Liabilities that are to be settled within twelve months from the balance sheet date;
 - (d) It does not have the right at the end of the reporting period to defer settlement of the liability at least twelve months after the reporting period.

(6) Cash equivalents

Cash equivalents refer to short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Time deposits that meet the definition above and are held for the purpose of meeting short-term cash commitments in operations are classified as cash equivalents.

(7) Financial assets at amortised cost

- A. Financial assets at amortised cost are those that meet all of the following criteria:
 - (a) The objective of the Group's business model is achieved by collecting contractual cash flows.
 - (b) The assets' contractual cash flows represent solely payments of principal and interest.
- B. On a regular way purchase or sale basis, financial assets at amortised cost are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs. Interest income from these financial assets is included in finance income using the effective interest method. A gain or loss is recognised in profit or loss when the asset is derecognised or impaired.
- D. The Group's time deposits which do not fall under cash equivalents are those with a short maturity period and are measured at initial investment amount as the effect of discounting is immaterial.

(8) Accounts and notes receivable

- A. Accounts and notes receivable entitle the Group a legal right to receive consideration in exchange for transferred goods or rendered services.
- B. The short-term accounts and notes receivable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(9) Impairment of financial assets

For financial assets at amortised cost including accounts receivable that have a significant financing component, at each reporting date, the Group recognizes the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognizes the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable that do not contain a significant financing component, the Group recognizes the impairment provision for lifetime ECLs.

(10) Derecognition of financial assets

The Group derecognises a financial asset when one of the following conditions is met:

- A. The contractual rights to receive the cash flows from the financial asset expire.
- B. The contractual rights to receive cash flows of the financial asset have been transferred and the Group has transferred substantially all risks and rewards of ownership of the financial asset.
- C. The contractual rights to receive cash flows of the financial asset have been transferred; however, the Group has not retained control of the financial asset.

(11) Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the weighted-average method. The cost of finish goods and work in progress comprises raw materials, direct labour, other direct costs and related production overheads (allocated based on normal operating capacity), but excludes borrowing costs. The item by item approach is used in applying the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

(12) Investments accounted for using equity method / associates

- A. Associates are all entities over which the Group has significant influence but not control. In general, it is presumed that the investor has significant influence, if an investor holds, directly or indirectly 20 percent or more of the voting power of the investee. Investments in associates are accounted for using the equity method and are initially recognised at cost.
- B. The Group's share of its associates' post-acquisition profits or losses is recognised in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income. When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Group does not recognise further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.

- C. When changes in an associate's equity do not arise from profit or loss or other comprehensive income of the associate and such changes do not affect the Group's ownership percentage of the associate, the Group recognises the Group's share of change in equity of the associate in 'capital surplus' in proportion to its ownership.
- D. Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in the associates. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

(13) Property, plant and equipment

- A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalised.
- B. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
- C. Land is not depreciated. Other property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives. Each part of an item of property, plant, and equipment with a cost that is significant in relation to the total cost of the item must be depreciated separately.
- D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end. If expectations for the assets' residual values and useful lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change. The estimated useful lives of property, plant and equipment are as follows:

Buildings and structures	20 ~ 50 years
Machinery and equipment	3 ~ 10 years
Transportation equipment	3 ~ 5 years
Office equipment	3 ~ 5 years
Leasehold improvements	3 ~ 10 years
Other equipment	3 ~ 5 years

(14) Leasing arrangements (lessee) — right-of-use assets/ lease liabilities

- A. Leases are recognised as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. For short-term leases or leases of low-value assets, lease payments are recognised as an expense on a straight-line basis over the lease

term.

- B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of fixed payments, less any lease incentives receivable.

The Group subsequently measures the lease liability at amortised cost using the interest method and recognises interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognised as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.

- C. At the commencement date, the right-of-use asset is stated at cost comprising the amount of the initial measurement of lease liability.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognised as an adjustment to the right-of-use asset.

- D. For lease modifications that decrease the scope of the lease, the lessee shall decrease the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognise the difference between remeasured lease liability in profit or loss. For all other lease modifications, the right-of-use asset will be adjusted accordingly by the remeasurement of the lease liability.

(15) Intangible assets

- A. The intangible assets are stated at acquired cost and amortised on a straight-line basis over their estimated useful lives of 17 years.
- B. The technical skills -Esophagus acquired from an external party are not yet available for use, and therefore are not amortised. It will be tested for impairment annually.

(16) Impairment of non-financial assets

- A. The Group assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. Except for goodwill, when the circumstances or reasons for recognizing impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased carrying amount due to reversal should not be more than what the depreciated or amortized historical cost would have been if the impairment had not been recognised.
- B. The recoverable amounts of intangible assets with an indefinite useful life and intangible assets that have not yet been available for use are evaluated periodically. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

(17) Borrowings

Borrowings comprise short-term bank borrowings. Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

(18) Notes and accounts payable

- A. Accounts payable are liabilities for purchases of goods and notes payable are those resulting from operating and non-operating activities.
- B. The short-term notes and accounts payable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(19) Derecognition of financial liabilities

A financial liability is derecognised when the obligation specified in the contract is either discharged or cancelled or expires.

(20) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognised as expense in that period when the employees render service.

B. Pensions

(a) Defined contribution plans

For defined contribution plans, the contributions are recognised as pension expense when they are due on an accrual basis. Prepaid contributions are recognised as an asset to the extent of a cash refund or a reduction in the future payments.

(b) Defined benefit plans

- i. Net obligation under a defined benefit plan is defined as the present value of an amount of pension benefits that employees will receive on retirement for their services with the Group in current period or prior periods. The liability recognised in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The net defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The rate used to discount is determined by using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related pension liability; when there is no deep market in high-quality corporate bonds, the Group uses interest rates of government bonds (at the balance sheet date) instead.
- ii. Remeasurements arising on defined benefit plans are recognised in other comprehensive income in the period in which they arise and are recorded as retained earnings.
- iii. Past service costs are recognised immediately in profit or loss.

iv. Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. And, the related information is disclosed accordingly.

C. Termination benefits

Termination benefits are employee benefits provided in exchange for the termination of employment as a result from either the Group's decision to terminate an employee's employment before the normal retirement date, or an employee's decision to accept an offer of redundancy benefits in exchange for the termination of employment. The Group recognises expense as it can no longer withdraw an offer of termination benefits or it recognises relating restructuring costs, whichever is earlier. Benefits that are expected to be due more than 12 months after balance sheet date shall be discounted to their present value.

D. Employees' compensation and directors' and supervisors' remuneration

Employees' compensation and directors' and supervisors' remuneration are recognised as expense and liability, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates. If employee compensation is paid by shares, the Group calculates the number of shares based on the closing price at the previous day of the board meeting resolution.

(21) Employee share-based payment

For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognised as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognised is based on the number of equity instruments that eventually vest.

(22) Income tax

A. The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or items recognised directly in equity, in which cases the tax is recognised in other comprehensive income or equity.

- B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.
- C. Deferred tax is recognised, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated balance sheet. However, the deferred tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred tax is provided on temporary differences arising on investments in subsidiaries, except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled.
- D. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. At each balance sheet date, unrecognised and recognised deferred tax assets are reassessed.
- E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realise the asset and settle the liability simultaneously.
- F. The interim period income tax expense is recognised based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.
- G. If a change in tax rate is enacted or substantively enacted in an interim period, the Group recognises the effect of the change immediately in the interim period in which the change occurs. The effect of the change on items recognised outside profit or loss is recognised in other comprehensive income or equity while the effect of the change on items recognised in profit or loss is recognised in profit or loss.

(23) Share capital

- A. Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or stock options are shown in equity as a deduction, net of tax, from the proceeds.
- B. Where the Company repurchases the Company's equity share capital that has been issued, the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the Company's equity holders. Where such shares are subsequently reissued, the difference between their carrying amount and any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Company's equity holders.

(24) Dividends

Dividends are recorded in the Company's financial statements in the period in which they are resolved by the Company's shareholders. Cash dividends are recorded as liabilities; stock dividends are recorded as stock dividends to be distributed and are reclassified to ordinary shares on the effective date of new shares issuance.

(25) Revenue recognition

A. Sales of goods

- (a) The Group sells electronic products and equipment as an agent. Sales are recognised when control of the products has transferred and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, or the Group has objective evidence that all criteria for acceptance have been satisfied.
- (b) A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

B. Service income

- (a) The Group provides services related to cell extraction, culture and cell preparation. Labor service income is recognized as revenue during the contract period according to the degree of completion of the contract using the percentage of completion method, and contract costs are recognized as expenses during the period in which they are incurred. The degree of completion is calculated by reference to the estimated stage of completion of contract costs incurred for each contract up to the end of the reporting period, as a percentage of the estimated total costs of that contract.
- (b) The Group provides cell-related testing services. Labor service revenue is recognized when the control of the service transaction result is transferred to the customer, that is, when the transaction result is delivered to the customer and the Group has no outstanding performance obligations that may affect the customer's acceptance of the result.

(26) Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision-Maker. The Group's Chief Operating Decision-Maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors that makes strategic decisions.

5. Critical Accounting Judgements, Estimates and Key Sources of Assumption Uncertainty

The preparation of these consolidated financial statements requires management to make critical judgements in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year; and the related information is addressed below:

(1) Critical judgements in applying the Group's accounting policies

None.

(2) Critical accounting estimates and assumptions

Impairment assessment of intangible assets

The Group assesses impairment based on its subjective judgement and determines the separate cash flows of a specific group of assets, useful lives of assets and the future possible income and expenses arising from the assets depending on how assets are utilised and industrial characteristics. Any changes of economic circumstances or estimates due to the change of Group strategy might cause material impairment on assets in the future.

As of March 31, 2025, the Group recognised intangible assets, net of impairment loss, amounting to \$188,514.

6. Details of Significant Accounts

(1) Cash and cash equivalents

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Cash on hand and revolving funds	\$ 487	\$ 509	\$ 515
Checking accounts and demand deposits	459,463	393,153	772,430
Cash equivalents			
Time deposits	1,078,956	1,224,838	908,727
Short-term securities	-	-	180,000
	<u>\$ 1,538,906</u>	<u>\$ 1,618,500</u>	<u>\$ 1,861,672</u>

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

B. The Group has no cash and cash equivalents pledged to others.

(2) Financial assets at amortised cost

Items	March 31, 2025	December 31, 2024	March 31, 2024
Current items:			
Reserved accounts for demand deposits	\$ 9,800	\$ 14,300	\$ 14,400
Time deposits maturing in excess of three months	-	20,000	220,000
	\$ 9,800	\$ 34,300	\$ 234,400

A. Amounts recognised in profit or loss in relation to financial assets at amortised cost are listed below:

	Three-month periods ended March 31,	
	2025	2024
Interest income	\$ 67	\$ 78

B. As at March 31, 2025, December 31, 2024 and March 31, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at amortised cost held by the Group were \$9,800, \$34,300 and \$234,400, respectively.

C. Details of the Group's financial assets at amortised cost pledged to others as collateral are provided in Note 8.

D. Information relating to credit risk of financial assets at amortised cost is provided in Note 12(2). The counterparties of the Group's investments in certificates of deposit are financial institutions with high credit quality, so the Group expects that the probability of counterparty default is remote.

(3) Notes and accounts receivable

	March 31, 2025	December 31, 2024	March 31, 2024
Notes receivable	\$ 5	\$ 46	\$ 572
Accounts receivable	\$ 389,762	\$ 366,526	\$ 320,738
Less: Allowance for bad debts	(1)	-	-
	\$ 389,761	\$ 366,526	\$ 320,738

A. The ageing analysis of accounts receivable and notes receivable that were past due but not impaired is as follows:

	March 31, 2025		December 31, 2024		March 31, 2024	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not past due	\$ 360,268	\$ 5	\$ 335,332	\$ 46	\$ 304,814	\$ 506
Up to 30 days	24,783	-	30,017	-	11,225	66
31 to 90 days	4,577	-	1,017	-	4,008	-
Over 90 days	134	-	160	-	691	-
	\$ 389,762	\$ 5	\$ 366,526	\$ 46	\$ 320,738	\$ 572

The above ageing analysis was based on past due date.

- B. As at March 31, 2025, December 31, 2024 and March 31, 2024, accounts receivable and notes receivable were all from contracts with customers. And as of January 1, 2024, the balance of receivables from contracts with customers amounted to \$254,084 . .
- C. As at March 31, 2025, December 31, 2024 and March 31, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's notes and accounts receivable were \$5, \$46 and \$572; \$389,761, \$366,526 and \$320,738 respectively.
- D. Information relating to credit risk of accounts receivable and notes receivable is provided in Note 12(2).

(4) Inventories

	March 31, 2025		
	Cost	Allowance for valuation loss	Book value
Raw materials	\$ 15,474	(\$ 2,531)	\$ 12,943
Work in progress	1,406	-	1,406
Semi-finished goods	2,210	-	2,210
Finished goods	915	-	915
Merchandises	78,361	(13,257)	65,104
	<u>\$ 98,366</u>	<u>(\$ 15,788)</u>	<u>\$ 82,578</u>
	December 31, 2024		
	Cost	Allowance for valuation loss	Book value
Raw materials	\$ 13,193	(\$ 2,574)	\$ 10,619
Work in progress	1,616	-	1,616
Semi-finished goods	2,241	-	2,241
Finished goods	858	-	858
Merchandises	77,701	(15,638)	62,063
	<u>\$ 95,609</u>	<u>(\$ 18,212)</u>	<u>\$ 77,397</u>
	March 31, 2024		
	Cost	Allowance for valuation loss	Book value
Raw materials	\$ 10,190	(\$ 2,301)	\$ 7,889
Work in progress	523	-	523
Semi-finished goods	2,207	-	2,207
Finished goods	1,418	-	1,418
Merchandises	61,480	(21,894)	39,586
	<u>\$ 75,818</u>	<u>(\$ 24,195)</u>	<u>\$ 51,623</u>

	Three-month periods ended March 31,	
	2025	2024
Cost of goods sold	\$ 342,865	\$ 297,900
Loss of inventory scrap	389	105
(Gain) loss on decline in market value	(2,424)	124
	<u>\$ 340,830</u>	<u>\$ 298,129</u>

The Group reversed a previous inventory write-down because the Group actively sold inventories which were loss on decline in market value and obsolescence during the three-month period ended March 31, 2025.

(5) Investments accounted for using the equity method

	March 31, 2025	December 31, 2024	March 31, 2024
Up Cell Biomedical Inc.	<u>\$ 10,189</u>	<u>\$ 10,733</u>	<u>\$ 13,527</u>

A. The basic information of the associates that are material to the Group is as follows:

Company name	Principal place of business	Shareholding ratio			Nature of relationship	Methods of measurement
		March 31, 2025	December 31, 2024	March 31, 2024		
Up Cell Biomedical Inc.	Taiwan	29.23%	29.23%	29.23%	Note	Equity method

Note: The Group is the single largest shareholder of Up Cell Biomedical Inc., however, the Company does not have absolute voting power over the resolutions in the shareholders' meeting of the Up Cell Biomedical Inc.. Although the Company serves as a corporate director of Up Cell Biomedical Inc. and was elected as the chairman of the Board of Directors of Up Cell Biomedical Inc., the Company does not hold a majority of board seats, which shows that the Company does not have the actual ability to dominate the relevant activities. Thus, the Company has no control, but only has significant influence, over Up Cell Biomedical Inc..

B. The summarised financial information of the associates that are material to the Group is as follows:

(a) Balance sheet

	Up Cell Biomedical Inc.		
	March 31, 2025	December 31, 2024	March 31, 2024
Current assets	\$ 21,639	\$ 22,154	\$ 24,193
Non-current assets	9,089	5,534	13,458
Current liabilities	(2,381)	(1,384)	(1,786)
Non-current liabilities	(4,104)	(202)	(202)
Total net assets	<u>\$ 24,243</u>	<u>\$ 26,102</u>	<u>\$ 35,663</u>
Share in associate's net assets	\$ 7,087	\$ 7,631	\$ 10,425
Goodwill	3,102	3,102	3,102
Carrying amount of the associate	<u>\$ 10,189</u>	<u>\$ 10,733</u>	<u>\$ 13,527</u>

(b) Statement of comprehensive income

		Up Cell Biomedical Inc.	
		Three-month periods ended March 31,	
		2025	2024
Revenue		\$ 1,387	\$ -
Loss for the period from continuing operations		(\$ 1,861)	(\$ 4,633)
Other comprehensive income, net of tax		-	-
Total comprehensive loss		(\$ 1,861)	(\$ 4,633)
Dividends received from associates		\$ -	\$ -

(6) Property, plant and equipment

		2025						
		Land	Buildings and structures	Machinery	Office equipment	Other equipment	Work in progress	Total
At January 1								
Cost		\$ 17,209	\$ 150,504	\$ 128,786	\$ 46,010	\$ 30,478	\$ 497,441	\$ 870,428
Accumulated depreciation		-	(46,288)	(49,699)	(38,513)	(19,746)	-	(154,246)
		<u>\$ 17,209</u>	<u>\$ 104,216</u>	<u>\$ 79,087</u>	<u>\$ 7,497</u>	<u>\$ 10,732</u>	<u>\$ 497,441</u>	<u>\$ 716,182</u>
Opening net book amount as at January 1		\$ 17,209	\$ 104,216	\$ 79,087	\$ 7,497	\$ 10,732	\$ 497,441	\$ 716,182
Additions		-	-	10,801	1,194	-	112,932	124,927
Depreciation charge		-	(1,521)	(4,052)	(819)	(891)	-	(7,283)
Net exchange differences		-	-	-	2	1	-	3
Closing net book amount as at March 31		<u>\$ 17,209</u>	<u>\$ 102,695</u>	<u>\$ 85,836</u>	<u>\$ 7,874</u>	<u>\$ 9,842</u>	<u>\$ 610,373</u>	<u>\$ 833,829</u>
At March 31								
Cost		\$ 17,209	\$ 150,504	\$ 139,587	\$ 47,188	\$ 30,525	\$ 610,373	\$ 995,386
Accumulated depreciation		-	(47,809)	(53,751)	(39,314)	(20,683)	-	(161,557)
		<u>\$ 17,209</u>	<u>\$ 102,695</u>	<u>\$ 85,836</u>	<u>\$ 7,874</u>	<u>\$ 9,842</u>	<u>\$ 610,373</u>	<u>\$ 833,829</u>
		2024						
		Land	Buildings and structures	Machinery	Office equipment	Other equipment	Work in progress	Total
At January 1								
Cost		\$ 17,209	\$ 150,504	\$ 111,089	\$ 44,259	\$ 26,354	\$ 61,888	\$ 411,303
Accumulated depreciation		-	(40,203)	(36,882)	(36,663)	(16,563)	-	(130,311)
		<u>\$ 17,209</u>	<u>\$ 110,301</u>	<u>\$ 74,207</u>	<u>\$ 7,596</u>	<u>\$ 9,791</u>	<u>\$ 61,888</u>	<u>\$ 280,992</u>
Opening net book amount as at January 1		\$ 17,209	\$ 110,301	\$ 74,207	\$ 7,596	\$ 9,791	\$ 61,888	\$ 280,992
Additions		-	-	278	573	190	94,260	95,301
Depreciation charge		-	(1,521)	(2,826)	(881)	(634)	-	(5,862)
Net exchange differences		-	-	-	7	1	-	8
Closing net book amount as at March 31		<u>\$ 17,209</u>	<u>\$ 108,780</u>	<u>\$ 71,659</u>	<u>\$ 7,295</u>	<u>\$ 9,348</u>	<u>\$ 156,148</u>	<u>\$ 370,439</u>
At March 31								
Cost		\$ 17,209	\$ 150,504	\$ 111,366	\$ 45,174	\$ 26,647	\$ 156,148	\$ 507,048
Accumulated depreciation		-	(41,724)	(39,707)	(37,879)	(17,299)	-	(136,609)
		<u>\$ 17,209</u>	<u>\$ 108,780</u>	<u>\$ 71,659</u>	<u>\$ 7,295</u>	<u>\$ 9,348</u>	<u>\$ 156,148</u>	<u>\$ 370,439</u>

A. The abovementioned assets belonged to owner-occupied assets.

- B. There were no interest capitalized as part of property, plant and equipment for the three-month periods ended March 31, 2025 and 2024.
- C. Information about the property, plant and equipment that were pledged to others as collaterals is provided in Note 8.

(7) Leasing arrangements - lessee

- A. The Group leases various assets including land, buildings and business vehicles. Rental contracts are typically made for periods of 1 to 18 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose covenants, but leased assets may not be used as security for borrowing purposes.
- B. The lease term of parking space and warehouse shall not exceed 12 months, and the underlying asset of low value consists of printers.
- C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Land	\$ 54,757	\$ 55,754	\$ 57,184
Buildings	41,022	45,968	37,546
Transportation equipment	<u>424</u>	<u>515</u>	<u>788</u>
	<u>\$ 96,203</u>	<u>\$ 102,237</u>	<u>\$ 95,518</u>

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
	<u>Depreciation charge</u>	<u>Depreciation charge</u>
Land	\$ 995	\$ 969
Buildings	5,008	4,584
Transportation equipment	<u>91</u>	<u>91</u>
	<u>\$ 6,094</u>	<u>\$ 5,644</u>

- D. For the three-month periods ended March 31, 2025 and 2024, the additions to right-of-use assets amounted to \$0.
- E. The information on profit and loss accounts relating to lease contracts is as follows:

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
<u>Items affecting profit or loss</u>		
Interest expense on lease liabilities	\$ 475	\$ 428
Expense on short-term lease contracts	581	403
Expense on leases of low-value assets	50	37
Profit from lease modification	3	-

- F. For the three-month periods ended March 31, 2025 and 2024, the Group's total cash outflow for leases were \$7,212 and \$6,519, respectively.

(8) Intangible assets

	<u>2025</u>	<u>2024</u>
	Technical skills (Notes 1 and 2)	Technical skills (Notes 1 and 2)
At January 1		
Cost	\$ 277,933	\$ 277,933
Accumulated amortisation	(87,470)	(79,667)
	<u>\$ 190,463</u>	<u>\$ 198,266</u>
Opening net book amount as at January 1	\$ 190,463	\$ 198,266
Amortisation charge	(1,949)	(1,951)
Closing net book amount as at March 31	<u>\$ 188,514</u>	<u>\$ 196,315</u>
At March 31		
Cost	\$ 277,933	\$ 277,933
Accumulated amortisation	(89,419)	(81,618)
	<u>\$ 188,514</u>	<u>\$ 196,315</u>

Note 1: The Group's technical skills-Esophagus are not yet available for use, and therefore are not amortised. It will be amortised on a straight-line basis over their estimated useful life upon being available for use. In accordance with IAS 36, the intangible assets that are not yet available for use should at least be tested for impairment annually by comparing its recoverable amount and the carrying amount.

Note 2: The information about the intangible assets in terms of the capital expenditure contracted for at the balance sheet date but not yet incurred is provided in Note 9(2)C.

(9) Short-term borrowings

<u>Type of borrowings</u>	<u>March 31, 2025</u>	<u>Interest rate range</u>	<u>Collateral</u>
Bank borrowings			
Bank unsecured borrowings	\$ 219,000	2.20%~2.35%	None
Bank secured borrowings	<u>142,000</u>	2.23%~2.24%	Note 8
	<u>\$ 361,000</u>		
<u>Type of borrowings</u>	<u>December 31, 2024</u>	<u>Interest rate range</u>	<u>Collateral</u>
Bank borrowings			
Bank unsecured borrowings	\$ 180,000	2.20%~2.35%	None
Bank secured borrowings	<u>144,000</u>	0.50%~2.24%	Note 8
	<u>\$ 324,000</u>		

Type of borrowings	March 31, 2024	Interest rate range	Collateral
Bank borrowings			
Bank unsecured borrowings	\$ 131,000	2.12%~2.35%	None
Bank secured borrowings	163,000	0.50%~2.33%	Note 8
	<u>\$ 294,000</u>		

Interest expense recognised in profit or loss amounted to \$1,892 and \$1,653 for the three-month periods ended March 31, 2025 and 2024, respectively.

(10) Pensions

- A. (a) The Group and its domestic subsidiaries have a defined benefit pension plan in accordance with the Labor Standards Act, covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Labor Standards Act. Under the defined benefit pension plan, two units are accrued for each year of service for the first 15 years and one unit for each additional year thereafter, subject to a maximum of 45 units. Pension benefits are based on the number of units accrued and the average monthly salaries and wages of the last 6 months prior to retirement. The Group contributes monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan, the trustee, under the name of the independent retirement fund committee. Also, the Group would assess the balance in the aforementioned labor pension reserve account by the end of December 31, every year. If the account balance is insufficient to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Group will make contributions for the deficit by next March.
- (b) For the aforementioned pension plan, the Group recognised pension costs of (\$4) and \$4 for the three-month periods ended March 31, 2025 and 2024, respectively.
- (c) There are no expected contributions to the defined benefit pension plans of the Group for the year ending December 31, 2026.
- B. (a) Effective July 1, 2005, the Group has established a defined contribution pension plan (the "New Plan") under the Labor Pension Act (the "Act"), covering all regular employees with R.O.C. nationality. Under the New Plan, the Group contributes monthly an amount based on 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment.
- (b) The employee retirement plans of MetaTech(S) and MetaTech Ltd. were based on the defined contribution plan in accordance with the relevant regulations applied by the local government.

(c) MetaTech(SZ) has a defined contribution plan. Monthly contribution to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. The abovementioned contribution percentage for the three-month periods ended March 31, 2025 and 2024 were both 13%. Other than the monthly contributions, the Group has no further obligations.

(d) For the aforementioned pension plan, the Group recognised pension costs of \$2,398 and \$2,339 for the three-month periods ended March 31, 2025 and 2024, respectively.

(11) Share-based payment

A. For the three-month periods ended March 31, 2025 and 2024, the Group's share-based payment arrangements were as follows:

<u>The issuing companies</u>	<u>Type of arrangement</u>	<u>Grant date</u>	<u>Quantity granted</u>	<u>Contract period</u>	<u>Vesting conditions</u>
The Company	Employee stock options	2018.04.02	2,280 thousand shares	6 years	2 ~ 5 years' service
"	Employee stock options	2018.05.14	1,297 thousand shares	6 years	2 ~ 5 years' service
"	Employee stock options	2018.11.15	423 thousand shares	6 years	2 ~ 5 years' service
Subsidiary	Employee stock options	2022.03.22	1,000 thousand shares	7 years	3 ~ 6 years' service
"	Employee stock options	2022.12.16	1,063 thousand shares	7 years	3 ~ 6 years' service
"	Employee stock options	2023.03.17	500 thousand shares	7 years	3 ~ 6 years' service

B. Details of the share-based payment arrangements are as follows:

(a) The Company (No such situation on March 31, 2025)

	<u>2024</u>	
	<u>No. of options</u>	<u>Weighted-average exercise price (in dollars)</u>
Options outstanding at January 1	2,271,000	\$ 58.08
Options granted	-	-
Options expired	-	-
Options outstanding at March 31	<u>2,271,000</u>	58.08
Options exercisable at March 31	<u>\$ 2,271,000</u>	58.08

(b) Subsidiary

	2025		2024	
	No. of options	Weighted-average exercise price (in dollars)	No. of options	Weighted-average exercise price (in dollars)
Options outstanding at January 1	1,933,000	\$ 11.00	2,158,000	\$ 11.00
Options granted	(21,000)	11.00	-	-
Options outstanding at March 31	<u>1,912,000</u>	11.00	<u>2,158,000</u>	11.00
Options exercisable at March 31	<u>122,150</u>	11.00	<u>-</u>	-

C. The weighted-average stock price of stock options at exercise dates for the three-month period ended March 31, 2025 was \$24.18.

D. The expiry date and exercise price of stock options outstanding at balance sheet date are as follows:

(a) The Company (No such situation on March 31, 2025)

The issue date	The maturity date	March 31, 2024	
		No. of options	Exercise price (in dollars)
2018.04.02	2024.04.01	1,581,000	\$ 57.90
2018.05.14	2024.05.13	671,000	58.60
2018.11.15	2024.11.14	19,000	54.50

(b) The subsidiaries

The issue date	The maturity date	March 31, 2025		December 31, 2024	
		No. of options	Exercise price (in dollars)	No. of options	Exercise price (in dollars)
2022.03.22	2029.03.21	349,000	\$ 11.00	370,000	\$ 11.00
2022.12.16	2029.12.15	1,063,000	11.00	1,063,000	11.00
2023.03.17	2030.03.16	500,000	11.00	500,000	11.00

The issue date	The maturity date	March 31, 2024	
		No. of options	Exercise price (in dollars)
2022.03.22	2029.03.21	595,000	\$ 11.00
2022.12.16	2029.12.15	1,063,000	11.00
2023.03.17	2030.03.16	500,000	11.00

E. The fair value of stock options granted on grant date is measured using the Black-Scholes option-pricing model. Relevant information is as follows:

Type of arrangement	Grant date	Stock price	Exercise price	Expected price volatility	Expected option life	Expected dividends	Risk-free interest rate	Fair value per unit
Employee stock options	2018.04.02	58.5	58.5	44.54~46.90% (Note)	4 ~ 5.5 years	-	0.64~0.76%	20.61~24.70
Employee stock options	2018.05.14	59.2	59.2	44.25~47.03% (Note)	4 ~ 5.5 years	-	0.67~0.76%	20.76~25.07
Employee stock options	2018.11.15	55.0	55.0	40.56~48.61% (Note)	4 ~ 5.5 years	-	0.73~0.83%	17.88~24.44
Employee stock options	2022.3.22	11.9	11.0	24.85~29.58%	5 ~ 6.5 years	-	0.73%	3.1~4
Employee stock options	2022.12.16	35.5	11.0	26.24~29.86%	5 ~ 6.5 years	-	1.18%	25.2~25.5
Employee stock options	2023.03.17	35.5	11.0	26.24~29.86%	5 ~ 6.5 years	-	1.18%	25.2~25.5

Note: The expected price volatility is estimated based on the annualised standard deviation by reference to the historical daily rate of returns of the Company (code: 3224) over the length of period approximating the expected option life.

F. Expenses incurred on share-based payment transactions are shown below:

	Three-month periods ended March 31,	
	2025	2024
Equity-settled	\$ 2,537	\$ 2,586

(12) Share capital

A. As of March 31, 2025, the Company's authorised capital was \$2,000,000, consisting of 200 million shares of ordinary stock (including 15 million shares reserved for employee stock options), and the paid-in capital was \$681,726, consisting of 68,133 thousand shares outstanding, with a par value of \$10 (in dollars) per share. All proceeds from shares issued have been collected. The number of the Company's ordinary shares outstanding at the beginning and end of the period was the same.

B. Treasury shares

(a) Reason for share reacquisition and movements in the number of the Company's treasury shares are as follows:

		March 31, 2025	
Name of company holding the shares	Reason for reacquisition	Number of shares	Carrying amount
The Company	To be reissued to employees	40,000	\$ 1,864
		December 31, 2024	
Name of company holding the shares	Reason for reacquisition	Number of shares	Carrying amount
The Company	To be reissued to employees	40,000	\$ 1,864
		March 31, 2024	
Name of company holding the shares	Reason for reacquisition	Number of shares	Carrying amount
The Company	To be reissued to employees	40,000	\$ 1,864

- (b) Pursuant to the R.O.C. Securities and Exchange Act, the number of shares bought back as treasury share should not exceed 10% of the number of the Company's issued and outstanding shares and the amount bought back should not exceed the sum of retained earnings, paid-in capital in excess of par value and realised capital surplus.
 - (c) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should not be pledged as collateral and is not entitled to dividends before it is reissued.
 - (d) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should be reissued to the employees within five years from the reacquisition date and shares not reissued within the five-year period are to be retired. Treasury shares to enhance the Company's credit rating and the stockholders' equity should be retired within six months of acquisition.
- C. The Company's shareholders' meeting on June 27, 2024, resolved to conduct a cash capital increase through a private placement. The purpose of the cash capital increase is to increase operating capital, with the maximum number of shares for private placement set at 10,000 thousand shares, each with a par value of 10 NTD. The rights and obligations of the newly issued common shares in this private placement, aside from the restrictions on circulation and transfer as stipulated by the Securities and Exchange Act, require that they must be held for three years from the date of delivery and that a public offering must be completed before applying for listing and trading. All other aspects are the same as those of the existing common shares. As of May 8, 2025, no private placement procedures have been conducted.

(13) Capital surplus

Pursuant to the Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. However, capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

(14) Accumulated deficit

- A. Under the Company's Articles of Incorporation, the current year's earnings, if any, shall first be used to pay all taxes and offset prior years' operating losses and then 10% of the remaining amount shall be set aside as legal reserve. The remaining earnings along with unappropriated earnings of prior years will be retained or distributed as proposed by the Board of Directors and resolved by the shareholders. Regarding the bonus distributed to the shareholders, cash dividends shall account for at least 30% of the total distribution and the remainder is distributed in shares.
- B. Except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion

in excess of 25% of the Company's paid-in capital.

- C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.
- D. The Company incurred accumulated deficit as of the three-month periods ended March 31, 2025 and 2024 respectively, and thus had no earnings for distribution.

(15) Operating revenue

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods and services over time and at a point in time in the following geographical regions:

	Three-month period ended March 31, 2025						
	Hong Kong and	Southeast	Taiwan		Others	Write-offs	Total
	Mainland China	Asia	Electronics	Biomedicine			
Total segment revenue	\$ 101,551	\$ 79,476	\$ 197,845	\$ 9,672	\$ 44	(\$ 1,310)	\$ 387,278
Inter-segment revenue	(205)	-	(447)	(652)	(6)	1,310	-
Revenue from external customer contracts	<u>\$ 101,346</u>	<u>\$ 79,476</u>	<u>\$ 197,398</u>	<u>\$ 9,020</u>	<u>\$ 38</u>	<u>\$ -</u>	<u>\$ 387,278</u>
Timing of revenue recognition							
At a point in time	\$ 101,346	\$ 79,476	\$ 197,398	\$ 8,501	\$ 38	\$ -	\$ 386,759
Over time	-	-	-	519	-	-	519
	<u>\$ 101,346</u>	<u>\$ 79,476</u>	<u>\$ 197,398</u>	<u>\$ 9,020</u>	<u>\$ 38</u>	<u>\$ -</u>	<u>\$ 387,278</u>
	Three-month period ended March 31, 2024						
	Hong Kong and	Southeast	Taiwan		Others	Write-offs	Total
	Mainland China	Asia	Electronics	Biomedicine			
Total segment revenue	\$ 98,173	\$ 126,336	\$ 106,651	\$ 1,410	\$ 95	(\$ 2,577)	\$ 330,088
Inter-segment revenue	(657)	-	(1,869)	-	(51)	2,577	-
Revenue from external customer contracts	<u>\$ 97,516</u>	<u>\$ 126,336</u>	<u>\$ 104,782</u>	<u>\$ 1,410</u>	<u>\$ 44</u>	<u>\$ -</u>	<u>\$ 330,088</u>
Timing of revenue recognition							
At a point in time	\$ 97,516	\$ 126,336	\$ 104,782	\$ 432	\$ 44	\$ -	\$ 329,110
Over time	-	-	-	978	-	-	978
	<u>\$ 97,516</u>	<u>\$ 126,336</u>	<u>\$ 104,782</u>	<u>\$ 1,410</u>	<u>\$ 44</u>	<u>\$ -</u>	<u>\$ 330,088</u>

B. Contract liabilities

The Group has recognised the following revenue-related contract liabilities:

	March 31, 2025	December 31, 2024	March 31, 2024	January 1, 2024
Contract liabilities:				
Advance sales receipts	<u>\$ 24,652</u>	<u>\$ 24,863</u>	<u>\$ 19,120</u>	<u>\$ 13,605</u>

(a) Significant changes in contract liabilities

None.

- (b) Revenue recognised that was included in the contract liability balance at the beginning of the period.

	Three-month periods ended March 31,	
	2025	2024
Revenue recognised that was included in the contract liability balance at the beginning of the period		
Advance sales receipts	\$ 7,993	\$ 5,524

(16) Interest Income

	Three-month periods ended March 31,	
	2025	2024
Interest income from bank deposits	\$ 8,015	\$ 11,455
Interest income from financial assets measured at amortised cost	67	78
Other interest income	14	5
	\$ 8,096	\$ 11,538

(17) Other gains and losses

	Three-month periods ended March 31,	
	2025	2024
Net currency exchange gains	\$ 11,206	\$ 16,845
Profit from lease modification	3	-
	\$ 11,209	\$ 16,845

Note : The information regarding impairment loss of non-financial assets is provided in Note 6(9).

(18) Financial cost

	Three-month periods ended March 31,	
	2025	2024
Interest expense:		
Bank borrowings	\$ 1,892	\$ 1,653
Lease liabilities	475	428
	\$ 2,367	\$ 2,081

(19) Expenses by nature

Function Nature	Three-month periods ended March 31,					
	2025			2024		
	Classified as Operating Costs	Classified as Operating Expenses	Total	Classified as Operating Costs	Classified as Operating Expenses	Total
Employee benefit expense	\$ 4,681	\$ 54,696	\$ 59,377	\$ 4,473	\$ 51,755	\$ 56,228
Consultancy fee	-	3,954	3,954	-	3,410	3,410
Depreciation expense	4,735	8,642	13,377	4,674	6,832	11,506
Amortisation expense	1,985	721	2,706	1,951	289	2,240

(20) Employee benefit expense

	Three-month periods ended March 31,	
	2025	2024
Wages and salaries	\$ 46,343	\$ 44,634
Labour and health insurance fees	3,880	3,607
Employee stock options	2,537	2,586
Pension costs	2,394	2,343
Directors' remuneration	2,210	1,360
Other personnel expenses	2,013	1,698
	<u>\$ 59,377</u>	<u>\$ 56,228</u>

- A. Under the amended Company's Articles of Incorporation, the current year's earnings, if any, shall first be reserved to cover the accumulated deficit. The remainder, if any, shall be distributed as employees' compensation at 1%-5%.
- B. As of March 31, 2025, and 2024, no employees' compensation and directors' remuneration were accrued due to the accumulated deficit of the Company. Information about employees' compensation and directors' remuneration of the Company as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(21) Income tax

A. Income tax expense

(a) Components of income tax expense :

	Three-month periods ended March 31,	
	2025	2024
Current tax:		
Current tax on profits for the period	\$ 1,061	\$ 1,371
Deferred tax:		
Origination and reversal of temporary differences	(219)	1,599
Income tax expense	<u>\$ 842</u>	<u>\$ 2,970</u>

- (b) The income tax (charge)/credit relating to components of other comprehensive income is as follows:

	Three-month periods ended March 31,	
	2025	2024
Currency translation differences	<u>(\$ 1,355)</u>	<u>(\$ 4,166)</u>

- B. The Company's income tax returns through 2023 have been assessed and approved by the Tax Authority.

(22) Losses per share

	<u>Three-month period ended March 31, 2025</u>		
	<u>Amount after tax</u>	<u>Weighted average number of ordinary shares outstanding (share in thousands)</u>	<u>Losses per share (in dollars)</u>
<u>Basic losses per share</u>			
Loss attributable to ordinary shareholders of the parent	(\$ <u>13,472</u>)	<u>68,133</u>	(\$ <u>0.20</u>)
	<u>Three-month period ended March 31, 2024</u>		
	<u>Amount after tax</u>	<u>Weighted average number of ordinary shares outstanding (share in thousands)</u>	<u>Losses per share (in dollars)</u>
<u>Basic losses per share</u>			
Loss attributable to ordinary shareholders of the parent	(\$ <u>25,341</u>)	<u>68,133</u>	(\$ <u>0.37</u>)

For the three-month period ended March 31, 2025 and 2024, the employee stock options and convertible bonds issued by the Group were excluded from the calculation of diluted losses per share since such options and bonds were anti-dilutive.

(23) Transactions with non-controlling interest

The Group did not participate in the capital increase raised by a subsidiary proportionally to its interest to the subsidiary

The Group's subsidiary, Locus Cell Co., Ltd., had changes in equity due to the conversion of employee stock options issued for the year ended December 31, 2025. This transaction resulted in an increase in the non-controlling interest by \$223 and an increase in the equity attributable to owners of the parent by \$8.

(24) Supplemental cash flow information

Investing activities with partial cash payments

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
Purchase of property, plant and equipment	\$ 124,927	\$ 95,301
Add: Opening balance of payable on equipment	17,606	1,762
Less: Ending balance of payable on equipment	(<u>65,019</u>)	(<u>7,027</u>)
Cash paid during the period	<u>\$ 77,514</u>	<u>\$ 90,036</u>

(25) Changes in liabilities from financing activities

	2025			
	<u>Short-term borrowings</u>	<u>Lease liabilities</u>	<u>Guarantee deposits received</u>	<u>Liabilities from financing activities</u>
At January 1	\$ 324,000	\$ 108,567	\$ 300	\$ 432,867
Changes in cash flow from financing activities	37,000	(6,106)	-	30,894
Impact of changes in foreign exchange rate	-	161	-	161
Changes in other non-cash items	-	(100)	-	(100)
At March 31	<u>\$ 361,000</u>	<u>\$ 102,522</u>	<u>\$ 300</u>	<u>\$ 463,822</u>

	2024			
	<u>Short-term borrowings</u>	<u>Lease liabilities</u>	<u>Guarantee deposits received</u>	<u>Liabilities from financing activities</u>
At January 1	\$ 294,000	\$ 107,319	\$ 300	\$ 401,619
Changes in cash flow from financing activities	-	(5,651)	-	(5,651)
Impact of changes in foreign exchange rate	-	93	-	93
At March 31	<u>\$ 294,000</u>	<u>\$ 101,761</u>	<u>\$ 300</u>	<u>\$ 396,061</u>

7. Related Party Transactions

(1) Names of related parties and relationship

<u>Names of related parties</u>	<u>Relationship with the Company</u>
Up Cell Biomedical Inc.	Investee company accounted for using the equity method
SHAREHOPE MEDICINE CO., LTD.	Other related party

(2) Significant related party transactions

A. Purchases

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
Purchases of goods:		
Associates	\$ 1,255	\$ -
Other related party	6	-
	<u>\$ 1,261</u>	<u>\$ -</u>

The Group purchases goods from the abovementioned related parties. The prices and terms are determined in accordance with mutual agreement, and the payment term is 30~60 days after monthly billings.

B. Payables to related parties

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Accounts payable:			
Associates	\$ 160	\$ 360	\$ -
Other related party	6	-	-
	<u>\$ 166</u>	<u>\$ 360</u>	<u>\$ -</u>
Other payables-			
acquisition of property,			
plant and equipment:			
Associates	<u>\$ 139</u>	<u>\$ 105</u>	<u>\$ 139</u>

C. Lease transactions — lessee

(a) The Group leases buildings from associates. Rental contracts are typically made for three years. Rents are paid at the end of the month.

(b) Lease liabilities

(i) Outstanding balance:

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Associates	<u>\$ -</u>	<u>\$ 296</u>	<u>\$ 1,190</u>

(ii) Interest expense:

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
Associates	<u>\$ -</u>	<u>\$ 6</u>

D. Operating cost

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
Rent expense:		
Associates	<u>\$ 153</u>	<u>\$ 65</u>

It is mainly the rent paid to the associates on a monthly basis.

(3) Key management compensation

	<u>Three-month periods ended March 31,</u>	
	<u>2025</u>	<u>2024</u>
Salaries and other short-term employee benefits	\$ 8,901	\$ 8,465
Share-based payment	1,729	1,729
Post-employment benefits	121	94
	<u>\$ 10,751</u>	<u>\$ 10,288</u>

8. Pledged Assets

The Group's assets pledged as collateral are as follows:

Pledged asset	Book value			Purpose
	March 31, 2025	December 31, 2024	March 31, 2024	
Financial assets at amortised cost				
-Reserved accounts for demand deposits	\$ 9,800	\$ 14,300	\$ 14,400	Guarantee for customs, credit card, performance bond of lease agreements and limit on short-term borrowings
Property, plant and equipment				
-Land	17,209	17,209	17,209	Guarantee for short-term credit line
-Buildings and structures	23,716	23,914	24,507	"
	<u>\$ 50,725</u>	<u>\$ 55,423</u>	<u>\$ 56,116</u>	

9. Significant Contingent Liabilities and Unrecognised Contract Commitments

(1) Contingencies

- A. The former chairman of the Company and the former CEO of its subsidiary Locus Cell Co., Ltd. and the former employee of the information department were suspected of stealing, leaking or using the company's confidential information during their tenure. The Company and its subsidiary Locus Cell Co., Ltd. appointed a lawyer and filed a complaint. As of May 8, 2025, the investigation of the aforementioned case has been concluded, and is currently being indicted by the Taiwan Taipei District Prosecutors Office. The Company's assessment had no significant impact on the financial statements.
- B. In 2023, the Group has received an attorney's letter from CellSeed Inc., a company based in Japan, claiming the termination of the cooperation contract signed by both parties due to the Group's alleged breach of contract. In order to protect the Group's own interests, the Group has appointed Japanese attorneys to file a lawsuit of confirming the contractual relationship to the Tokyo District Court. As of May 8, 2025, the aforementioned case is still on trial.

(2) Commitments

- A. As of March 31, 2025, December 31, 2024 and March 31, 2024, guaranteed notes as well as endorsements and guarantees amounting to \$16,603 (USD 500 thousand), \$16,393 (USD 500 thousand) and \$16,000 (USD 500 thousand), respectively, were issued for subsidiaries' borrowings.
- B. The joint credit line of the Group and its third-tier subsidiary, MetaTech Ltd., for financial institution short-term secured borrowings was NTD 85 million as of March 31, 2025, December 31, 2024 and March 31, 2024. As of March 31, 2025, December 31, 2024 and March 31, 2024, the promissory notes amounting to NTD 85 million was issued to a bank as guarantee and the abovementioned joint credit line all amounting to NTD 85 million.
- C. Capital expenditure contracted for at the balance sheet date but not yet incurred is as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Property, plant and equipment	\$ 458,478	\$ 528,659	\$ 861,822
Intangible assets (Note)	31,986	29,449	17,964
	<u>\$ 490,464</u>	<u>\$ 558,108</u>	<u>\$ 879,786</u>

Note: The Group entered into a start-up agreement of cell sheet regenerative medical cooperation with Japan CellSeed Inc. on December 21, 2016 with the consideration amounting to JPY 50 million for expanding biomedical research and development, business development, as well as promoting the Group's innovative transformation of regenerative medicine. The Board of Directors during its meeting on March 24, 2017 adopted a resolution to enter into a cooperation agreement of abovementioned cell sheet regenerative medicine with Japan CellSeed Inc., which was formally signed on April 24, 2017 with the consideration amounting to JPY 1.25 billion. As of March 31, 2025, the Group has paid JPY 1,246,727,004 in respect of the payment schedule for arrangement. For information on foregoing cooperation agreement, please refer to Note 9(1)B.

10. Significant Disaster Loss

None.

11. Significant Events After the Balance Sheet Date

To fulfil the Group's working capital, capital needs for future development and to bring in strategic investors, the Board of Directors of the Group during their meeting on May 8, 2025 proposed to raise additional cash through private placement by issuing ordinary shares within 10,000 thousand shares in instalments. As of May 8, 2025, the issuance has not yet been resolved by the shareholders.

12. Others

(1) Capital management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Group may issue new shares or sell assets to reduce debt.

(2) Financial instruments

A. Financial instruments by category

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
<u>Financial assets</u>			
Financial assets at amortised cost			
Cash and cash equivalents	\$ 1,538,906	\$ 1,618,500	\$ 1,861,672
Financial assets at amortised cost	9,800	34,300	234,400
Notes receivable	5	46	572
Accounts receivable	389,761	366,526	320,738
Other receivables	3,846	4,581	2,671
Guarantee deposits paid (shown as 'other non-current assets')	7,794	7,908	7,686
	<u>\$ 1,950,112</u>	<u>\$ 2,031,861</u>	<u>\$ 2,427,739</u>

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
<u>Financial liabilities</u>			
Financial liabilities at amortised cost			
Short-term borrowings	\$ 361,000	\$ 324,000	\$ 294,000
Notes payable	894	1,006	1,661
Accounts payable	134,622	137,347	79,001
Other payables	104,564	50,839	41,410
Guarantee deposits received (shown as ‘other non-current liabilities’)	300	300	300
	<u>\$ 601,380</u>	<u>\$ 513,492</u>	<u>\$ 416,372</u>
Lease liability	<u>\$ 102,522</u>	<u>\$ 108,567</u>	<u>\$ 101,761</u>

B. Financial risk management policies

- (a) The Group’s activities expose it to a variety of financial risks: market risk (including foreign exchange risk and interest rate risk), credit risk and liquidity risk.
- (b) Risk management is carried out by a central treasury department (Group treasury) under policies approved by the Board of Directors. Group treasury identifies, evaluates and hedges financial risks in close co-operation with the Group’s operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

C. Significant financial risks and degrees of financial risks

(a) Market risk

Exchange rate risk

- i. The Group operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to the USD. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- ii. Management has set up a policy to require group companies to manage their foreign exchange risk against their functional currency.
- iii. The Group has certain investments in foreign operations, whose net assets are exposed to foreign currency translation risk.
- iv. The Group’s businesses involve some non-functional currency operations (the Company’s functional currency: NTD; other certain subsidiaries’ functional currency: HKD and USD). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

March 31, 2025			
	Foreign currency amount (In thousands)	Exchange rate	Book value (NTD)
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 17,964	33.2050	\$ 596,495
USD:HKD	7,522	7.7800	249,768
JPY:NTD	343,949	0.2227	76,597
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	3,282	33.2050	108,979
USD:HKD	1,152	7.7800	38,252
December 31, 2024			
	Foreign currency amount (In thousands)	Exchange rate	Book value (NTD)
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 17,773	32.7850	\$ 582,688
USD:HKD	7,649	7.7653	250,772
JPY:NTD	348,224	0.2099	73,092
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	3,207	32.7850	105,141
USD:HKD	1,380	7.7653	45,243
March 31, 2024			
	Foreign currency amount (In thousands)	Exchange rate	Book value (NTD)
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 14,505	32.0000	\$ 464,160
USD:HKD	9,046	4.0890	289,472
JPY:NTD	360,491	0.2115	76,244
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	1,667	32.0000	53,344
USD:HKD	1,208	4.0890	38,656

- v. The total exchange gains including realized and unrealized arising from significant foreign exchange variation on the monetary items held by the Group for the three-month periods ended March 31, 2025 and 2024, amounted to \$11,206 and \$16,845, respectively.
- vi. Analysis of foreign currency market risk arising from significant foreign exchange variation:

<u>Three-month period ended March 31, 2025</u>			
<u>Sensitivity analysis</u>			
<u>Degree of variation</u>	<u>Effect on profit or loss before tax</u>	<u>Effect on other comprehensive income after tax</u>	
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	1%	\$ 5,965	\$ -
USD:HKD	1%	2,498	-
JPY:NTD	1%	766	-
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	1%	1,090	-
USD:HKD	1%	383	-
<u>Three-month period ended March 31, 2024</u>			
<u>Sensitivity analysis</u>			
<u>Degree of variation</u>	<u>Effect on profit or loss before tax</u>	<u>Effect on other comprehensive income after tax</u>	
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	1%	\$ 4,642	\$ -
USD:HKD	1%	2,895	-
JPY:NTD	1%	762	-
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	1%	533	-
USD:HKD	1%	387	-

(b) Credit risk

- i. Credit risk refers to the risk of financial loss to the Group arising from default by the clients on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable and notes receivable based on the agreed terms, as well as the contract cash flows of financial assets at amortised cost.

- ii. The Group manages their credit risk taking into consideration the entire group's concern. For banks and financial institutions, only above investment grade are accepted. According to the Group's credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the management . The utilisation of credit limits is regularly monitored. Credit risk arises from credit exposures to wholesale and retail customers, including outstanding receivables.
- iii. The Group adopts following assumptions under IFRS 9 to assess whether there has been a significant increase in credit risk on that instrument since initial recognition:
If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
- iv. The Group adopts the assumptions under IFRS 9, the default occurs when the contract payments are past due over 90 days.
- v. The following indicators are used to determine whether the credit impairment of debt instruments has occurred:
 - (i) It becomes probable that the issuer will enter bankruptcy or other financial reorganization due to their financial difficulties;
 - (ii) Default or delinquency in interest or principal repayments;
 - (iii) Adverse changes in national or regional economic conditions that are expected to cause a default.
- vi. The Group classifies customers' accounts receivable in accordance with credit rating of customer. The Group applies the simplified approach using loss rate methodology to estimate expected credit loss.
- vii. The Group wrote-off the financial assets, which cannot be reasonably expected to be recovered, after initiating recourse procedures. However, the Group will continue executing the recourse procedures to secure their rights. The Group had no right of financial assets that are still under recourse procedures on March 31, 2025, December 31, 2024 and March 31, 2024.
- viii. The Group incorporates forward-looking considerations into the future in the Business Observation Report of the Taiwan Economic Research Institute, and adjusts the loss rate established based on historical and current information for a specific period to estimate the allowance loss for accounts receivable (including related parties) and loss as at March 31, 2025, December 31, 2024 and March 31, 2024. The rate method is as follows:

	<u>Not past due</u>	<u>Up to 30 days past due</u>	<u>Up to 90 days past due</u>	<u>Over 90 days</u>	<u>Total</u>
<u>At March 31, 2025</u>					
Expected loss rate	0.03%	0.05%	0.07%	50%~100%	
Total book value	\$ 360,268	\$ 24,783	\$ 4,577	\$ 134	\$ 389,762
Loss allowance	-	-	-	1	1
	<u>Not past due</u>	<u>Up to 30 days past due</u>	<u>Up to 90 days past due</u>	<u>Over 90 days</u>	<u>Total</u>
<u>At December 31, 2024</u>					
Expected loss rate	0.03%	0.05%	0.07%	50%~100%	
Total book value	\$ 335,332	\$ 30,017	\$ 1,017	\$ 160	\$ 366,526
Loss allowance	-	-	-	-	-
	<u>Not past due</u>	<u>Up to 30 days past due</u>	<u>Up to 90 days past due</u>	<u>Over 90 days</u>	<u>Total</u>
<u>At March 31, 2024</u>					
Expected loss rate	0.03%	0.05%	0.07%	50%~100%	
Total book value	\$ 304,814	\$ 11,225	\$ 4,008	\$ 691	\$ 320,738
Loss allowance	-	-	-	-	-

- ix. The Group did not recognise loss allowance for accounts receivable applied using the simplified approach since it was not material for the three-month periods ended March 31, 2025 and 2024.

	<u>2025</u>	<u>2024</u>
At January 1	\$ -	\$ -
Provision for impairment loss	1	-
At March 31	<u>\$ 1</u>	<u>\$ -</u>

(c) Liquidity risk

- i. Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group treasury. Group treasury monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times. Such forecasting takes into consideration the Group's debt financing plans, covenant compliance, compliance with internal balance sheet ratio targets.
- ii. The table below analyses the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date for non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

Non-derivative financial liabilities

March 31, 2025	Less than 1 year	Between 1 and 5 years	Over 5 years
Short-term borrowings	\$ 363,144	\$ -	\$ -
Notes payable	894	-	-
Accounts payable	134,622	-	-
Other payables	104,564	-	-
Lease liability	25,469	44,588	40,119

Non-derivative financial liabilities

December 31, 2024	Less than 1 year	Between 1 and 5 years	Over 5 years
Short-term borrowings	\$ 325,870	\$ -	\$ -
Notes payable	1,006	-	-
Accounts payable	137,347	-	-
Other payables	50,839	-	-
Lease liability	26,961	47,821	43,051

Non-derivative financial liabilities

March 31, 2024	Less than 1 year	Between 1 and 5 years	Over 5 years
Short-term borrowings	\$ 295,787	\$ -	\$ -
Notes payable	1,661	-	-
Accounts payable	79,001	-	-
Other payables	41,410	-	-
Lease liability	26,005	46,937	43,546

(3) Fair value information

A. Financial instruments not measured at fair value

The carrying amounts of financial assets and financial liabilities not measured at fair value are approximate to their fair values. Including cash and cash equivalents, financial assets at amortised cost, notes receivable, accounts receivable, other receivables, guarantee deposit paid, short-term borrowings, notes payable, accounts payable, guarantee deposits received and other payables.

B. The fair value of financial instruments was both \$0 for the three-month periods ended March 31, 2025 and 2024, and therefore not disclosed.

13. Supplementary Disclosures

(1) Significant transactions information

A. Loans to others: Please refer to table 1.

B. Provision of endorsements and guarantees to others: Please refer to table 2.

C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): None.

D. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: None.

E. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: None.

F. Significant inter-company transactions during the reporting periods: Please refer to table 3.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Please refer to table 4.

(3) Information on investments in Mainland China

A. Information on investees in the Mainland Area: Please refer to table 5.

B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Please refer to table 3.

14. Operating Segment Information

(1) General information

Management has determined the reportable operating segments based on the reports reviewed by the Chief Operating Decision-Maker that are used to make strategic decisions. The Group considers the business from a geographic perspective. Management has determined the reportable operating segments based on the reports reviewed by the Chief Operating Decision-Maker that are used to make strategic decisions. The Group considers the business from a geographic perspective.

(2) Segment information

The segment information provided by the Group to the Chief Operating Decision-Maker for the reportable segments is as follows:

	Three-month period ended March 31, 2025						
	Hong Kong and Mainland China	Southeast Asia	Taiwan		Others	Write-offs	Total
			Electronics	Biomedicine			
	\$ 101,346	\$ 79,476	\$ 197,398	\$ 9,020	\$ 38	\$ -	\$ 387,278
Revenue from external customers							
Inter-segment revenue	205	-	447	652	6	(1,310)	-
Total segment revenue	\$ 101,551	\$ 79,476	\$ 197,845	\$ 9,672	\$ 44	(\$ 1,310)	\$ 387,278
Segment income (loss)	\$ 8,963	\$ 234	\$ 6,594	(\$ 70,376)	(\$ 957)	\$ 1,701	(\$ 53,841)
Depreciation and amortisation	\$ 909	\$ 314	\$ 553	\$ 15,977	\$ -	(\$ 1,670)	\$ 16,083
	Three-month period ended March 31, 2024						
	Hong Kong and Mainland China	Southeast Asia	Taiwan		Others	Write-offs	Total
			Electronics	Biomedicine			
	\$ 97,516	\$ 126,336	\$ 104,782	\$ 1,410	\$ 44	\$ -	\$ 330,088
Revenue from external customers							
Inter-segment revenue	657	-	1,869	-	51	(2,577)	-
Total segment revenue	\$ 98,173	\$ 126,336	\$ 106,651	\$ 1,410	\$ 95	(\$ 2,577)	\$ 330,088
Segment income (loss)	\$ 6,754	\$ 2,756	(\$ 10,731)	(\$ 61,932)	(\$ 279)	\$ 1,689	(\$ 61,743)
Depreciation and amortisation	\$ 1,201	\$ 269	\$ 602	\$ 13,346	\$ -	(\$ 1,672)	\$ 13,746

The Group did not provide information to the Chief Operating Decision-Maker with respect to the measurement amounts of total assets and liabilities for decision making.

(3) Reconciliation for segment income (loss)

The revenue from external customers reported to the Chief Operating Decision-Maker is measured in a manner consistent with that in the statement of comprehensive income.

A reconciliation of reportable segment income or loss to the income/(loss) before tax from continuing operations for the three-month periods ended March 31, 2025 and 2024 is provided as follows:

	Three-month periods ended March 31,	
	2025	2024
Reportable segments loss	(\$ 53,841)	(\$ 61,743)
Interest income	8,096	11,538
Other income	213	290
Other gains and losses	11,209	16,845
Finance costs	(2,367)	(2,081)
Share of loss of associates and joint ventures accounted for using the equity method	(544)	(1,354)
Loss before tax from continuing operations	<u>(\$ 37,234)</u>	<u>(\$ 36,505)</u>

Metatech (AP) Inc. and Subsidiaries
Loans to others
For the three-month period ended March 31, 2025

Table 1

Expressed in thousands of NTD
(Except as otherwise indicated)

No. (Note 1)	Creditor	Borrower	General ledger account	Is a related party	Maximum outstanding balance during the three- month period ended March 31, 2025	Balance at March 31, 2025	Actual amount drawn down	Interest rate	Nature of loan	Amount of transactions with the borrower	Reason for short-term financing	Allowance for doubtful accounts	Collateral		Limit on loans granted to a single party	Ceiling on total loans granted	Footnote
													Item	Value			
1	MTI Holding Co., Ltd.	MetaTech (S) Pte Ltd.	Other receivables	Y	66,410	66,410	-	6.77%	Short-term financing	-	Operations	-	-	-	413,313	516,641	Notes 4 and 5

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:

- (1)The Company is '0' .
- (2)The subsidiaries are numbered in order starting from '1'.

Note 2: According to the company's "Regulations for Provision of Loans", the interest rate of loans to others should be no less than the average interest rate of the Company's short-term funds borrowed from financial institutions at that time.

Note 3: According to the Company's "Regulations for Provision of Loans", the Company's ceiling on total loans granted to others are as follows:

- A. For business transactions, the accumulated loan amount is the transaction amount.
- B. For short-term financing, the total amount is lower than 40% of the creditor's net assets.
- C. The limit on total loans to the same party is 20% of the Company's net assets.

Note 4: According to the subsidiary's "Regulations for Provision of Loans", the subsidiary's ceiling on total loans granted to others are as follows:

- A. For business transactions, the accumulated loan amount is the transaction amount.
- B. For short-term financing, the total amount is lower than 100% of the creditor's net assets.
- C. The limit on total loans to the same party is 80% of the subsidiary's net assets.

The subsidiary's ceiling on total loans granted to related parties, which its 100% voting shares directly or indirectly held by the parent Company and to the same party is 100% and 80% of the subsidiary's net assets, respectively.

Note 5: The current period ending balance was translated into TWD at the exchange rate at the balance sheet date (1USD:33.205TWD).

Metatech (AP) Inc. and Subsidiaries
Provision of endorsements and guarantees to others
For the three-month period ended March 31, 2025

Table 2

Expressed in thousands of NTD
(Except as otherwise indicated)

Number (Note 1)	Endorser/ guarantor	Party being endorsed/guaranteed		Limit on endorsements/ guarantees provided for a single party	Maximum outstanding endorsement/ guarantee amount as of March 31, 2025	Outstanding endorsement/ guarantee amount at March 31, 2025	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company	Ceiling on total amount of endorsements/ guarantees provided	Provision of endorsements/ guarantees by parent company to subsidiary	Provision of endorsements/ guarantees by subsidiary to parent company	Provision of endorsements/ guarantees to the party in Mainland China	Footnote
		Company name	Relationship with the endorser/ guarantor											
0	Metatech (AP) Inc.	MetaTech Ltd.	The Company's third-tier subsidiary	\$ 567,698	\$ 16,603	\$ 16,603	\$ 16,603	\$ -	1.46	\$ 1,135,396	Y	N	N	Notes 2,3 and 6

Note 1: The numbers filled in for the endorsements/guarantees provided by the Company or subsidiaries are as follows:

(1)The Company is '0' .

(2)The subsidiaries are numbered in order starting from '1'.

Note 2: According to the Company's "Regulations for Provision of Endorsements and Guarantees", the Company's limit on endorsements/guarantees provided for a single party is 50% of the Company's net assets.

Note 3: According to the Company's "Regulations for Provision of Endorsements and Guarantees", the Company's limit on total endorsements/guarantees is 100% of the Company's net assets.

Note 4: According to the Subsidiary's "Regulations for Provision of Endorsements and Guarantees", the Subsidiary's limit on endorsements/guarantees provided for a single party is 50% of the Subsidiary's net assets.

Note 5: According to the Subsidiary's "Regulations for Provision of Endorsements and Guarantees", the Subsidiary's limit on total endorsements/guarantees is 100% of the Subsidiary's net assets.

Note 6: The current period ending balance was translated into TWD at the exchange rate at the balance sheet date (1USD: 33.205TWD).

Metatech (AP) Inc. and Subsidiaries
 Significant inter-company transactions during the reporting periods
 For the three-month period ended March 31, 2025

Table 4

Expressed in thousands of NTD
 (Except as otherwise indicated)

Number	Company name	Counterparty	Relationship (Note 2)	Transaction			Percentage of consolidated total operating revenues or total assets
				General ledger account	Amount	Transaction terms	
1	MetaTech Ltd.	MetaTech (Shenzhen) Ltd.	3	Advance sales receipts	12,289	Prices are determined according to the gross profits in mutual agreement, 90 days after monthly billing	0%

Note 1: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

- (1) Parent company is '0'.
- (2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between transaction company and counterparty is classified into the following three categories; fill in the number of category each case belongs to (If transactions between parent company and subsidiaries or between subsidiaries refer to the same transaction, it is not required to disclose twice. For example, if the parent company has already disclosed its transaction with a subsidiary, then the subsidiary is not required to disclose the transaction; for transactions between two subsidiaries, if one of the subsidiaries has disclosed the transaction, then the other is not required to disclose the transaction.):

- (1) Parent company to subsidiary.
- (2) Subsidiary to parent company.
- (3) Subsidiary to subsidiary.

Note 3: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.

Note 4: The sales prices and credit terms are the same with the third parties. The credit terms on sales to third parties were 30 to 120 days.

Note: Individual transactions less than \$5,000 will not be disclosed, and other related party transactions will not be disclosed separately.

Metatech (AP) Inc. and Subsidiaries
Information on investees
For the three-month period ended March 31, 2025

Table 5

Expressed in thousands of NTD
(Except as otherwise indicated)

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2024			Net profit (loss) of the investee for the three-month period ended March 31, 2025	Investment income (loss) recognised by the Company for the three-month period ended March 31, 2025	Footnote
				Balance as at December 31, 2024	Balance as at December 31, 2023	Number of shares	Ownership (%)	Book value			
Metatech (AP) Inc.	MetaTech Investment Holding Co., Ltd.	British Virgin Islands	Investment holding and reinvestment business	\$ 333,065	\$ 333,065	10,000,000	100	\$ 516,641	\$ 8,895	\$ 8,895	Subsidiary
Metatech (AP) Inc.	Chienhwa Travel Service Co.,Ltd.	Taiwan	Travel business	4,900	4,900	1,050	100	2,525	(191)	(191)	Subsidiary
Metatech (AP) Inc.	Up Cell Biomedical Inc.	Taiwan	Cell sheet development and medical production	38,000	38,000	3,800,000	29.23	10,189	(1,861)	(544)	Investee accounted for using the equity method
Metatech (AP) Inc.	LOCUS CELL CO., LTD.	Taiwan	Cell therapy phase available product and commissioned to manufacturing services	300,000	300,000	30,000,000	15	254,437	(28,946)	(4,369)	Subsidiary
MetaTech Investment Holding Co., Ltd.	MTI Holding Co., Ltd.	Samoa	Investment holding and reinvestment business	333,065	333,065	10,000,000	100	516,641	8,895	8,895	Sub-subsiidiary
MTI Holding Co., Ltd.	MetaTech (S) Pte Ltd.	Singapore	Wholesale and retail of electronic materials	82,259	82,259	3,800,000	100	140,877	293	293	Third-tier subsidiary
MTI Holding Co., Ltd.	MetaTech Ltd.	Hong Kong	Wholesale and retail of electronic materials	199,170	199,170	46,000,000	100	296,984	8,589	8,589	Third-tier subsidiary
LOCUS CELL CO., LTD.	Locus Ltd.	Japan	Sales of Regenerative Medicine Products	223	-	100	100	88	(131)	(131)	Sub-subsiidiary

Metatech (AP) Inc. and Subsidiaries
Information on investments in Mainland China
For the three-month period ended March 31, 2025

Table 6

Expressed in thousands of NTD
(Except as otherwise indicated)

Investee in Mainland China	Main business activities	Paid-in capital	Investment method (Note1)	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China / Amount remitted back to Taiwan for the three-month period ended March 31, 2025		Accumulated amount of remittance from Taiwan to Mainland China as of March 31, 2025	Net income of investee as of March 31, 2025	Ownership held by the Company (direct or indirect)	Investment income (loss) recognized by the Company for the three-month period ended March 31, 2025 (Note 2)	Book value of investments in Mainland China as of March 31, 2025	Accumulated amount of investment income remitted back to Taiwan as of March 31, 2025	Footnote
					Remitted to Mainland China	Remitted back to Taiwan							
MetaTech (Shenzhen) Ltd.	Wholesale and retail of electronic materials	\$ 87,207	Through investing in an existing company in the third areas, which then invested in the investee in Mainland China	\$ 87,207	\$ -	\$ -	\$ 87,207	(\$ 394)	100	(\$ 394)	\$ 68,988	\$ -	Notes 1, 2 and 3

Company name	Accumulated amount of remittance from Taiwan to Mainland China as of March 31, 2025	Investment amount approved by the Investment Commission of the Ministry of Economic Affairs (MOEA)	Celling on investments in Mainland China imposed by the Investment Commission of MOEA (Note 4)
Metatech (AP) Inc.	\$ 87,207	\$ 88,203	\$ 1,546,429

Note 1: Through investing in the subsidiary, MetaTech Investment Holding Co, Ltd in the third areas by cash and reinvesting by its second-tier subsidiary, MetaTech Ltd. The investments were approved by the Investment Commission of the Ministry of Economic Affairs.

Note 2: The amount of investment income (loss) recognised is the amount recognised in the financial statements of the investee that were reviewed by R.O.C parent company's CPA.

Note 3: Paid-in capital and investment amount are translated into TWD at exchange rate at the balance sheet date (1USD: 33.205 TWD).

Note 4: According to the MOEA Regulation No. 09704604680, "Regulations Governing the Permission of Investment or Technical Cooperation in Mainland Area", announced on August 29, 2008, limit on accumulated amount of investment in Mainland China is the higher of 60% of net assets and consolidated net assets.